top of page

New York Times: How A Pharmaceutical Company Exploited U.S. Patent System to Make Billions

Wednesday, February 8, 2023


In 2016, a blockbuster drug called Humira was poised to become a lot less valuable.

The key patent on the best-selling anti-inflammatory medication, used to treat conditions like arthritis, was expiring at the end of the year. Regulators had blessed a rival version of the drug, and more copycats were close behind. The onset of competition seemed likely to push down the medication’s $50,000-a-year list price...



ความคิดเห็น


bottom of page